<DOC>
	<DOCNO>NCT01588028</DOCNO>
	<brief_summary>CH5424802 newly invent , selective oral ALK inhibitor . In Phase I portion , goal determine follow : dose limit toxicity , maximum tolerate dose , pharmacokinetic ( PK ) parameter , recommend dose .</brief_summary>
	<brief_title>A Clinical Study Testing The Safety Efficacy CH5424802/RO5424802 Patients With ALK Positive Non-Small Cell Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>ECOG performance status = &lt; 2 Confirmed ALKpositive NSCLC FDA approve kit NSCLC fail crizotinib treatment Phase I Measurable disease define RECIST 1.1 Adequate hematologic , hepatic , renal function Prior therapy ALK inhibitor crizotinib Brain metastasis , symptomatic and/or require treatment History serious cardiac dysfunction Clinically significant gastrointestinal abnormality would affect absorption drug Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>